Portfolio company news

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG


Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

3 April 2014

AMCo appoints Claudio Albrecht as Global Strategic Adviser

Amdipharm Mercury Group ('AMCo' or 'the Group'), the international niche pharmaceuticals company, today announces that it has appointed Claudio Albrecht as a Global Strategic Adviser with immediate effect.

Claudio Albrecht has more than 26 years' experience in the global pharmaceutical and generics industries. Until recently, he was CEO and Chairman of the Board of the Actavis Group, a global integrated speciality pharmaceutical company, which became the third largest generics company worldwide following the acquisition by US company Watson.

Claudio was formerly CEO of the Ratiopharm Group, one of Europe's leading generics companies headquartered in Germany. He started his pharmaceutical career at Sandoz, the generic pharmaceuticals division of Novartis, where he had responsibility for running the Sandoz generics businesses in the Netherlands, Germany and the US respectively.

John Beighton, CEO of AMCo, said:

"Claudio has an exceptional track record in the global generics industry. We believe that his experience will be invaluable to AMCo. The AMCo Executive Team looks forward to working closely with him in support of the Group's growth strategy and to focus on achieving our goal of becoming a truly international leader in the niche pharmaceutical industry."

Claudio Albrecht added:

"Since its formation in 2012, AMCo has delivered outstanding performance.  I have been impressed by the AMCo team, who have already made significant strides in internationalising the business.  I am looking forward to bringing my expertise to help accelerate the Group's expansion through acquisitions and organically."

AMCo is a rapidly growing international pharmaceuticals company committed to bringing its portfolio of niche medicines to patients in more than 100 countries. AMCo was formed in 2012 following the merger of Mercury Pharma and Amdipharm.  Since then, the business has grown significantly and the Group now has global revenues approaching US$500 million.  In December 2013 AMCo acquired Abcur AB, a speciality pharmaceutical business in the Nordic region. Last April 2013 it acquired Fucithalmic, a global ophthalmic product.